登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：688222 证券简称：成都先导 公告编号：2025-018 重要内容提示： ● 本次增持主体宁波聚智先导生物科技合伙企业（有限合伙）（以下简称"聚智先导"）为成都先导药物 开发股份有限公司（以下简称"公司"或"成都先导"）持股5%以上股东、员工持股平台，与公司控股股 东、实际控制人JIN LI（李进）为一致行动人关系。截至本公告披露日，聚智先导持有公司38,651,163 股股份，占总股本的比例为9.65%，JIN LI（李进）持有公司81,876,948股股份，占总股本的比例为 20.43%，聚智先导与JIN LI（李进）合计持有公司120,528,111股股份，占总股本的比例为30.08%。 ● 成都先导于今日收到公司控股股东、实际控制人JIN LI（李进）的一致行动人聚智先导的通知，基于 对公司未来持续稳定发展的信心以及对公司股票长期投资价值的认可，聚智先导拟自本公告披露之日起 12个月内，通过包括但不限于集中竞价、大宗交易等上海证券交易所交易系统允许的方式增持公司股 份，合计增持金额不低于人民币2,500万元（含）且不高于人民币5,000万 ...

Group 1 - Recent announcements indicate a surge in share buyback plans by listed companies, driven by confidence in future growth and stock value [1][2][3] - Chengdu Xian Dao plans to increase its shares by an amount between 25 million and 50 million yuan, funded by its own capital and a special loan from Industrial Bank [1] - Hongli Zhihui's major shareholder intends to buy back shares worth between 25 million and 50 million yuan within six months, using self-raised funds [2] Group 2 - Sanfeng Environment's major shareholder has already purchased 256,300 shares and plans to invest between 150 million and 300 million yuan in further buybacks over the next year [2] - Tunnel Shares' major shareholder has received a loan commitment from Industrial Bank for up to 450 million yuan to support share buybacks, having already acquired 21.83 million shares [2] - Hubei Yihua's major shareholder has secured a loan commitment of up to 360 million yuan for stock buybacks, with plans to invest between 200 million and 400 million yuan starting from May 2025 [3]

Group 1 - Hongchuang Holdings plans to acquire 100% equity of Shandong Hongtuo Industrial for 63.518 billion yuan, transforming from a single aluminum deep processing business to a full industry chain including electrolytic aluminum, alumina, and aluminum deep processing [3] - LIZHU Group intends to acquire 64.81% of Vietnam's Imexpharm Corporation for approximately 1.587 billion yuan, enhancing its presence in the pharmaceutical sector [4][5] - China Power Construction reported a new contract amount of 386.49 billion yuan from January to April, a year-on-year decrease of 4.9% [7] Group 2 - Wanhua Chemical announced a scheduled maintenance for its production facilities, including a five-month technical upgrade for its Yantai ethylene unit, which will not significantly impact operations [8] - Changhong High-Tech received a warning letter from the Ningbo Securities Regulatory Bureau for failing to disclose related party transactions in a timely manner [9] - Highgreat plans to invest 10 million yuan in Blue Core Computing, which focuses on RISC-V architecture chips [10] Group 3 - Xidi Micro plans to increase capital by 30 million USD in its wholly-owned subsidiary Hong Kong Xidi Micro to support its expanding business [12] - Bichuang Technology lost its high-tech enterprise qualification, resulting in an increase in corporate income tax rate from 15% to 25% for the years 2023 to 2025 [13] - Tonghua Dongbao intends to transfer 5.7% of its shares in Xiamen Tebao Biological Engineering for a total of 1.301 billion yuan [16] Group 4 - Tian Tie Technology signed a strategic cooperation agreement with Shenzhen Xinjie Energy to collaborate on solid-state battery lithium metal anode materials [23] - Nanjing Port disclosed that its stock trading has shown signs of market sentiment overheating, indicating potential irrational trading behavior [24] - Zhongnan Media signed a government procurement contract worth 1.009 billion yuan, ensuring stable revenue for its main business [25]

Group 1 - Yong'an Pharmaceutical announced that its stock price has seen a significant short-term increase, indicating a risk of market sentiment overheating, although there are no major changes in the company's fundamentals [3] - China Power Construction reported that from January to April 2025, the company signed new contracts worth 386.49 billion yuan, a decrease of 4.9% year-on-year [4] - Wanhua Chemical announced a scheduled maintenance for its production facilities, including a technical upgrade for its ethylene unit, which is expected to last approximately five months, while ensuring that other units continue to operate normally [5] Group 2 - Changhong High-Tech received a warning letter from the Ningbo Securities Regulatory Bureau for failing to timely disclose related party transactions exceeding expected amounts, with the company secretary held responsible [6] - Gaweida plans to invest 10 million yuan in Blue Core Computing, acquiring a 0.6729% stake in the company, which focuses on RISC-V architecture chip solutions [7] Group 3 - Zhongnan Media signed a government procurement contract worth 1.009 billion yuan, ensuring stable revenue from educational materials for the 2025 fiscal year [9] - Hongli Zhihui's controlling shareholder plans to increase their stake in the company by investing between 25 million and 50 million yuan [11] - Xingye Co.'s controlling shareholder intends to reduce their stake by up to 1% of the total share capital due to personal asset allocation needs [12] - Chengdu Xian Dao's employee stockholding platform plans to invest between 25 million and 50 million yuan to increase its stake in the company, with no set price range for the purchase [13]

次增持计划不触及要约收购，不会导致公司控股股东及实际控制人发生变 化。 相关风险提示：本次增持计划实施可能存在因资本市场情况发生变化等因 素，导致增持计划延迟实施或无法完成实施的风险。如增持计划实施过程 中出现上述风险情形，公司将及时履行信息披露义务，敬请广大投资者注 意投资风险。 一、增持主体的基本情况 证券代码：688222 证券简称：成都先导 公告编号：2025-018 成都先导药物开发股份有限公司关于 宁波聚智先导生物科技合伙企业（有限合伙） 增持公司股份计划的公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次增持主体宁波聚智先导生物科技合伙企业（有限合伙）（以下简称"聚 智先导"）为成都先导药物开发股份有限公司（以下简称"公司"或"成都先 导"）持股 5%以上股东、员工持股平台，与公司控股股东、实际控制人 JIN LI（李进）为一致行动人关系。截至本公告披露日，聚智先导持有公司 38,651,163 股股份，占总股本的比例为 9.65%，JIN LI（李进）持有公司 81,876,9 ...

成都先导公告，持股5%以上股东聚智先导计划2500万元-5000万元增持公司股份，资金来源为自有资金 及专项贷款。 ...

Group 1 - The core viewpoint of the article highlights Chengdu Xian Dao's current stock performance, with a closing price of 15.82 yuan, an increase of 1.54%, and a rolling PE ratio of 96.48, marking a new low in 20 days, with a total market value of 6.339 billion yuan [1] - Chengdu Xian Dao ranks 40th in the medical services industry based on PE ratio, which has an average of 38.66 and a median of 38.36 [1] - As of March 31, 2025, the number of shareholders for Chengdu Xian Dao has increased to 16,254, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] Group 2 - The main business of Chengdu Xian Dao includes drug early discovery and development services related to DEL technology, offering services such as DEL screening, DEL library customization, FBDD/SBDD, custom drug development, compound structure intellectual property transfer, and chemical synthesis [1] - In the latest quarterly report for Q1 2025, the company achieved an operating income of 107 million yuan, a year-on-year decrease of 0.60%, while net profit reached 28.2844 million yuan, a year-on-year increase of 102.90%, with a gross profit margin of 51.87% [1]

证券代码：688222 证券简称：成都先导 公告编号：2025-017 成都先导药物开发股份有限公司 关于筹划重大资产重组事项的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 风险提示 本次交易不构成关联交易。经初步测算，本次交易预计构成《上市公司重大 资产重组管理办法》规定的重大资产重组情形。本次交易不涉及公司发行股份， 也不会导致公司控制权的变更。 二、本次筹划重大资产重组事项的进展情况 2025 年 3 月 31 日，公司与标的公司及其控股股东、实际控制人邹巧根签署 了《股权收购意向书》，内容详见公司于 2025 年 4 月 1 日在上海证券交易所网站 （www.sse.com.cn）披露的《成都先导药物开发股份有限公司关于筹划重大资产 重组暨签署<股权收购意向书>的提示性公告》（公告编号：2025-004）。 截至本公告披露之日，公司及有关各方正在积极推进本次重组的相关工作， 具体方案仍在谨慎筹划论证中，公司将继续按照《上市公司重大资产重组管理办 法》及其他相关规定，及时履行信息披露义务。 三、风险提示 ...

证券代码：688222 证券简称：成都先导 成都先导药物开发股份有限公司 2024 年年度股东大会会议资料 2024 年年度股东大会会议资料目录 | 2024 | 年年度股东大会会议资料目录 2 | | | --- | --- | --- | | 2024 | 年年度股东大会会议须知 | 3 | | 2024 | 年年度股东大会会议议程 | 6 | | 2024 | 年年度股东大会会议议案 | 8 | | 议案一：关于审议公司 | 年年度报告及其摘要的议案 2024 | 8 | | 议案二：关于审议公司 | 2024 年度董事会工作报告的议案 | 9 | | 议案三：关于审议公司 | 2024 年度监事会工作报告的议案 | 16 | | 议案四:关于审议公司 | 年度财务决算报告的议案 2024 | 20 | | 议案五：关于审议公司 | 2024 年度利润分配预案的议案 24 | | | 议案六：关于续聘公司 | 年度财务及内部控制审计机构的议案 25 2025 | | | 议案七：关于审议公司 | 2025 年度财务预算报告的议案 26 | | | 议案八：关于审议公司 | 2025 年度董事薪酬方案的议 ...

Investment Rating - The report maintains a "Recommended" rating for Chengdu Xian Dao (688222.SH) [4][6] Core Views - Chengdu Xian Dao achieved a revenue of 427 million yuan in 2024, representing a year-on-year increase of 14.99%, and a net profit attributable to shareholders of 51 million yuan, up 26.13% year-on-year [1] - In Q1 2025, the company reported a revenue of 107 million yuan, a slight decline of 0.60% year-on-year, while the net profit attributable to shareholders surged by 102.90% to 28 million yuan [1][2] - The gross margin for Q1 2025 improved to 48.13%, an increase of 2.92 percentage points year-on-year and 5.83 percentage points quarter-on-quarter [2] - The company is focusing on enhancing its foundational capabilities through AI integration, which is expected to accelerate drug discovery processes [4] Summary by Sections Financial Performance - In 2024, the revenue breakdown by business segments shows: 1. DEL segment generated 199 million yuan, up 8.55% year-on-year 2. FBDD/SBDD segment achieved 120 million yuan, up 30.99% year-on-year 3. OBT segment reported 48 million yuan, up 39.72% year-on-year [3] - The projected revenues for 2025-2027 are 515 million, 614 million, and 722 million yuan, with growth rates of 20.6%, 19.1%, and 17.7% respectively [4][6] Profitability Metrics - The net profit attributable to shareholders is forecasted to be 65 million, 84 million, and 103 million yuan for 2025, 2026, and 2027, with growth rates of 27.3%, 28.9%, and 22.7% respectively [6][9] - The PE ratios for the same years are projected to be 91, 71, and 58 [6][9] Strategic Initiatives - The company has successfully built a DMTA molecular optimization infrastructure combining DEL and AI, which enhances the efficiency of drug development [4] - The integration of AI is expected to reduce trial and error costs while accelerating the transition from target discovery to clinical candidates [4]